Despite the growing evidence base, current utilisation of SGLT2-inhibitors remains below the number of patients eligible for treatment,20 with higher prescribing rates among heart failure patients who also have T2DM compared with those without T2DM.21 Here, SLC5A2 is linked to heart failure.